Eligibility criteria
The retrieved reports will be screened according to the checklist (Additional 1) and the eligibility criteria shown below including participants, interventions, controls, types of study, and other criteria.
► Participants
Inclusion: the participants suffering from and required treatment for stable angina pectoris.
Exclusion: the participants suffering from unstable angina pectoris or other complicated heart disease conditions.
► Interventions
Inclusion: any RCT that evaluates the efficacy of these thirteen drugs. Exclusion: any RCT that evaluates other drugs or combined treatments of multiple drugs.
► Controls
Inclusion: any RCT that evaluates the efficacy of these thirteen drugs other than the drug of intervention. Exclusion: any RCT that evaluates other drugs or combined treatments of multiple drugs.
► Types of study
Inclusion: only RCTs will be included. Exclusion: Observational cohort and case-control studies, case reports, experimental studies and reviews will be excluded.
► Other criteria
Other inclusion criteria: any RCT that includes outcome measures of symptomatic relief, electrocardiography tests, exercise tests, heart rates, or blood pressures. Other exclusion criteria are (a) duplicated or redundant studies, and (b) combined treatments with multiple drugs.
Study selection
Reviewers will screen all titles or abstracts or full texts for database records independently according to the eligibility criteria. Disagreements between reviewers in screening results will be resolved by consensus. Selection process of relevant studies retrieved from databases will be shown in a PRISMA-compliant flowchart (Figure 1 in Additional). dosages of treatment, (g) adverse events (AEs), and (h) outcome measures including ECG tests, SYM relief, exercise tests, heart rates, and blood pressures. The data will be standardized (Table 1 in Additional). The quality of eligible studies will be evaluated according to the Cochrane Collaboration's risk of bias tool for assessing risk of bias (Table 2 in Additional) [9] .
Outcome measures
Outcome measures of anti-anginal efficacy include electrocardiography (ECG) tests, symptomatic (SYM) relief, exercise tests, heart rates, and blood pressures [2, 3] . Primary outcomes are ECG tests, SYM relief, and exercise tests. Secondary outcomes are heart rates and blood pressures.
Statistical analysis
Network meta-analysis will be conducted with WinBUGS Version 1. 4.3 [12] and "R2WinBUGS" package [13] in R software [14] . A Bayesian random-effects model [11, 15] will be adopted: ‫ݎ‬ ் is the number of success events in the treatment T in the ith RCT;
‫‬ ் is the probability of treatment response;
݊ ் is the number of all events in the treatment T in the ith RCT; ߜ ் is the random effect of T relative to C in the ith RCT;
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ߪ ௗ ଶ is the variance of ݀ ் distribution, which is a numeric choice;
ߪ is the standard deviation of ߜ ் ; and ‫ݏ‬ is a numeric choice of uniform prior.
This Bayesian model and WinBUGS codes are as specified in the research reports published by the Agency for Healthcare Research and Quality (AHRQ) [11] and the National Institute for
Health and Clinical Excellence (NICE) [16, 17] . Model fitness will be assessed with the deviance information criterion (DIC) and the posterior mean of the total residual deviance [18] . Deviance measures the fit of the model to the data using the likelihood function. The DIC is a statistic that measures Bayesian model fit and penalizes the deviance by the model complexity. Variances and consistencies among all comparisons are assessed using the Brooks-Gelman-Rubin method under a random-effects model [19] . Bayesian models will be executed with the WinBUGS settings:
chains at 4, refresh at 100, thinning intervals at 10, and update at 20000. The overall effect size will be presented by odds ratios with their 95% credible intervals for dichotomous outcomes [20] .
Continuous outcomes will be computed by mean differences with their 95% credible intervals [20] .
The overall ranking will be determined by network meta-analysis according to overall effect sizes.
The ranks are ranged between 1 and 13 (number of drugs). Rank 1 is the best and the Rank 13 is the worst.
Subgroup analysis will be performed based on the specified outcomes [17] . Sensitivity analyses will be performed on evidence quality evaluated by the Cochrane Collaboration's risk of bias tool. Consistency analysis will be performed with "metafor" package [21] and "combinat"
package [22] in R software. Mann-Whitney-Wilcoxon test [23] and Kendall rank correlation [24] will be performed with statistical software R to determine the agreement among the rankings based on different outcome measures. p values lower than 0.05 will be considered statistically significant.
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Ethical issues
No ethical approval is required because this study include no confidential personal data and interventions with the patients.
Publication plan
This protocol has been registered (Registration number: CRD42014007113) with the PROSPERO (International Prospective Register of Systematic Reviews) [25] . The procedures of this systematic review and network meta-analysis will be conducted in accordance with the PRISMA-compliant guideline [26] . Details of this systematic review and network meta-analysis will be submitted to an open access and peer reviewed journal.
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SL conceived the study. SL and YJ wrote the protocol and approved the final manuscript.
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Competing interests
None declared.
Provenance and peer review
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Methods and analyses:
Randomized controlled trials (RCT) on the drug therapy of stable angina pectoris with multiple outcome measures, selected from symptomatic relief, electrocardiography tests, exercise tests, heart rates, and blood pressures etc., will be included. Overall effect sizes will be represented as mean differences with 95% credible intervals (CrI) for continuous outcome data and as odds ratios with 95% CrI for dichotomous outcome data. Bayesian network meta-analysis by WinBUGS will be conducted to compare the efficacies of these drugs. Sensitivity analysis on the quality of RCTs and subgroup analysis on the category of included drugs will be performed.
Ethics and dissemination:
Ethical approval is not required because this study include no confidential personal data and interventions on the patients. Network meta-analysis is based on the RCT reports of eligible drugs in treating stable angina pectoris. The results of this study will be disseminated by an open access and peer-reviewed publication.
Protocol registration:
PROSPERO CRD42014007113. 
Key messages
Included drugs will be evaluated by a Bayesian network meta-analysis.
Systematic review and network meta-analysis will compare the efficacy of drugs with multiple outcomes.
Strengths and limitations of this study
Network meta-analysis together with sensitivity analysis, subgroup analysis, and consistency analysis will evaluate the efficacies of multiple anti-anginal drugs.
This study will provide evidence for clinical decision-makers to formulate better treatment of stable angina pectoris.
This study is inherently retrospective and based on the published RCTs only. Available meta-analysis of randomized and crossover trials comparing BBs, CCBs, and nitrates suggested that BBs provide similar clinical outcomes and are associated with fewer adverse events than CCBs for patients with stable angina pectoris [4] . Meta-analysis of efficacy of monotherapy compared with combined anti-anginal drugs for treating stable angina pectoris suggested that the combined therapy with CCBs and BBs is more effective than monotherapy [5] .
A systematic review and meta-analysis of randomized trials with nitrates for stable angina pectoris suggested that long-term administration of nitrates is beneficial for angina prophylaxis and improves exercise performance but might be ineffective for improving quality of life [6] . Another systematic review and meta-analysis of randomized controlled trials on long-term BBs for stable angina pectoris suggested that BBs may decrease the rates of death and unstable angina when compared with no treatment but are no more effective than other anti-anginal agents on prophylaxis of myocardial ischemia [7] . Meta-analysis of randomized trials of beta-blockers for stable angina suggested that BBs do not have statistically significant impact on mortality versus placebo or versus other active comparators [8] . The latest meta-analysis on anti-anginal drugs was published in 2012 [8] . All of these systematic reviews performed only pairwise meta-analysis to As the number (n) of available treatments increasing, the required number ‫ܥ(‬ ଶ ) of pairwise meta-analysis increases exponentially. Therefore, pairwise meta-analysis for comparing multiple treatments is labor-intensive and time-consuming. The Cochrane Handbook regards multiple treatments comparisons (MTC) as a highly relevant and useful technique to evaluate and rank treatments, although the Handbook does not describe the methods for MTC [9] . Bayesian network meta-analyses were proposed for evaluating the efficacies of MTC [10, 11] . The most related
Bayesian meta-analytic study was on other classes of anti-anginal drugs (i.e. trimetazidine versus other non-heart rate lowering anti-anginal medications) and was not monotherapy [12] , while the present study was on monotherapy with BBs, CCBs, and nitrates.
This study is a comprehensive network meta-analysis on the efficacies of BBs, CCBs, and nitrates in treating stable angina pectoris.
OBJECTIVES
The objective of this study is to compare efficacies of common anti-anginal drugs by Bayesian network meta-analysis on randomized controlled trials.
METHODS AND ANALYSIS
Design
Systematic review and Bayesian network meta-analysis.
Information sources
Clinical trial reports will be searched from major databases including PubMed, ScienceDirect, Cochrane Library, and EMBASE.
Search strategies
Keywords used in search strategies include "angina" and "random". For example, the following search strategy will be used in searching PubMed and other English databases: 
Eligibility criteria
The retrieved reports will be screened according to the checklist of eligibility (Appendix 1) and the eligibility criteria shown below including participants, interventions, controls, types of study, and other criteria.
► Participants
Inclusion: the participants suffering from and requiring treatment for stable angina pectoris.
► Interventions
► Controls
► Types of study
► Other criteria
Study selection
Reviewers will screen all titles or abstracts or full texts for database records independently according to the eligibility criteria. Disagreements between reviewers in screening results will be dosages of treatment, (g) adverse events (AEs), and (h) outcome measures including ECG tests, SYM relief, exercise tests, heart rates, and blood pressures. The data will be standardized ( Table 1 ).
The quality of eligible studies will be evaluated according to the Cochrane Collaboration's risk of bias tool for assessing risk of bias (Table 2 ) [9] .
Outcome measures
Statistical analysis
Network meta-analysis will be conducted with WinBUGS Version 1.4.3 [13] and "R2WinBUGS" package [14] in R software [15] . A Bayesian random-effects model [11, 16] will be adopted:
where T is the treatment (a specific arm) of the RCT;
C is the control (the baseline arm) of the RCT and T ≠ C; i is number index of RCT;
‫ݎ‬ ் is the number of success events in the treatment T in the ith RCT;
‫‬ ் is the probability of treatment response; This Bayesian model and WinBUGS codes are as specified in the research reports published by the Agency for Healthcare Research and Quality (AHRQ) [11] and the National Institute for
Health and Clinical Excellence (NICE) [17, 18] . Model fitness will be assessed with the deviance information criterion (DIC) and the posterior mean of the total residual deviance [19] . Deviance measures the fit of the model to the data using the likelihood function. The DIC is a statistic that measures Bayesian model fit and penalizes the deviance by the model complexity. Variances and consistencies among all comparisons are assessed using the Brooks-Gelman-Rubin method under a random-effects model [20] . Bayesian models will be executed with the WinBUGS settings:
chains at 4, refresh at 100, thinning intervals at 10, and update at 20000. The overall effect size will be presented by odds ratios with their 95% credible intervals for dichotomous outcomes [21] .
Continuous outcomes will be computed by mean differences with their 95% credible intervals [21] .
Subgroup analysis will be performed based on the specified outcomes [18] . Sensitivity analyses will be performed on evidence quality evaluated by the Cochrane Collaboration's risk of bias tool. Consistency analysis will be performed with "metafor" package [22] and "combinat"
package [23] in R software. Mann-Whitney-Wilcoxon test [24] and Kendall rank correlation [25] will be performed with statistical software R to determine the agreement among the rankings based on different outcome measures. p values lower than 0.05 will be considered statistically significant. 
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A systematic review and meta-analysis of randomized trials with nitrates for stable angina pectoris suggested that long-term administration of nitrates is beneficial for angina prophylaxis and improves exercise performance but might be ineffective for improving quality of life [6] . Another systematic review and meta-analysis of randomized controlled trials on long-term BBs for stable angina pectoris suggested that BBs may decrease the rates of death and unstable angina when compared with no treatment but are no more effective than other anti-anginal agents on prophylaxis of myocardial ischemia [7] . Meta-analysis of randomized trials of beta-blockers for stable angina suggested that BBs do not have statistically significant impact on mortality versus placebo or versus other active comparators [8] . The latest meta-analysis on anti-anginal drugs was published in 2012 [8] . All of these systematic reviews performed only pairwise meta-analysis to
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